{"canonical":"https://abierto.us/opportunities/75n95024q00549","key":"75N95024Q00549","url":"https://abierto.us/opportunities/75n95024q00549","title":"Skin Biopsy Testing for Deep Phenotyping Projects at the National Institute of Neurological Diseases and Stroke (NINDS)","solicitation_number":"75N95024Q00549","notice_type":"s","open":false,"response_deadline":"2024-08-29T14:00:00Z","first_posted":"2024-08-23","last_posted":"2024-09-04","department":"HEALTH AND HUMAN SERVICES, DEPARTMENT OF","subagency":"NATIONAL INSTITUTES OF HEALTH","office":"NATIONAL INSTITUTES OF HEALTH","naics":"334516","psc":null,"set_aside":null,"place_state":"MD","place_county":"24031","place_county_name":"Montgomery County","place_city":"2407125","place_city_name":"Bethesda","winner":"AUTOMATE SCIENTIFIC, INC","award_amount":null,"publications":[{"notice_id":"36f21dca319f420c8d352213f7a20903","title":"Zeitz Glass Microelectrode Puller or Equal","solicitation_number":"75N95024Q00549","notice_type":"r","base_type":"r","posted":"2024-08-23","posted_at":null,"due_at":"2024-08-29T14:00:00Z","due_date":"2024-08-29","cancelled":null,"archived":null,"archive_date":"2024-09-13","award_number":null,"awardee_name":null,"amount":null,"link_sam":"https://sam.gov/workspace/contract/opp/36f21dca319f420c8d352213f7a20903/view","enriched":false,"history":[]},{"notice_id":"949e3b121b784d54980f443558331678","title":"Skin Biopsy Testing for Deep Phenotyping Projects at the National Institute of Neurological Diseases and Stroke (NINDS)","solicitation_number":"75N95024Q00549","notice_type":"s","base_type":"s","posted":"2024-09-04","posted_at":null,"due_at":"2024-09-09T19:00:00Z","due_date":"2024-09-09","cancelled":null,"archived":null,"archive_date":"2024-09-24","award_number":null,"awardee_name":null,"amount":null,"link_sam":"https://sam.gov/workspace/contract/opp/949e3b121b784d54980f443558331678/view","enriched":false,"history":[]}],"latest_notice_id":"949e3b121b784d54980f443558331678","first_type":"r","notices":[{"dates":{"posted":"2024-08-23","response_deadline":{"raw":"2024-08-29T10:00:00-04:00","utc":"2024-08-29T14:00:00Z","date":"2024-08-29","time":"10:00:00","utc_offset_seconds":-14400}},"links":{"sam":"https://sam.gov/workspace/contract/opp/36f21dca319f420c8d352213f7a20903/view"},"naics":{"codes":["334516"],"primary":"334516"},"title":"Zeitz Glass Microelectrode Puller or Equal","agency":{"office":{"code":"75N950","name":"NATIONAL INSTITUTES OF HEALTH NIDA"},"subtier":{"code":"7529","name":"NATIONAL INSTITUTES OF HEALTH"},"department":{"code":"075","name":"HEALTH AND HUMAN SERVICES, DEPARTMENT OF"},"office_address":{"zip":"20892","city":"Bethesda","state":"MD","country":"USA"},"organization_type":"OFFICE"},"status":{"active":false,"archive_date":"2024-09-13","archive_type":"auto15"},"contacts":[{"name":"Cassandra Conley","role":"primary","email":"cassandra.conley@nih.gov"}],"base_type":{"code":"r","label":"Sources Sought"},"notice_id":"36f21dca319f420c8d352213f7a20903","provenance":{"extract":{"url":"https://s3.amazonaws.com/falextracts/Contract%20Opportunities/Archived%20Data/FY2024_archived_opportunities.csv","etag":"\"d582488fe153a9f11bf629913d176ffc-137\"","fetched_at":"2026-09-16T19:07:39.720164Z","row_sha256":"53dc0326847166eac1903809033aa883c817335bc6afeb9c8b5a7d6f77a795f3","last_modified":"2026-09-13T14:47:40Z"},"updated_at":"2026-09-16T19:07:39.720164Z","first_seen_at":"2026-09-16T19:07:39.720164Z"},"description":{"text":"This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. For equipment/supply requirements, small business responses must include: (1) the place of manufacturing (i.e. address if supply/equipment is a domestic end product and include country of manufacture), as well as (2) the size status of the manufacturer under the applicable NAICS code (i.e. address Non-Manufacturer Rule). Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Background: Research in the Cellular Neurophysiology Section focuses on circuit and cellular properties of neurons located in the midbrain dopamine system and basal ganglia. As a major part of our research, we are interested in the physiology of dopamine neurons located in the substantia nigra pars compacta (SNc) that undergo selective cell death in Parkinson’s patients. Specifically, we are interested in understanding how synaptic and intrinsic conductances expressed on these neurons (particularly calcium permeable conductances, ie voltage gated calcium channels and glutamate activated receptors) differ among subpopulations dopamine neurons. The hope that this information may provide insight to why SNc dopamine neurons are particularly vulnerable in Parkinson’s disease. Our goal is to identify novel physiological and genetic markers in single SNc dopamine neurons which may be useful in defining subpopulations of these neurons in a meaningful way. In order to study the action potential firing properties and physiology of dopamine system neurons, our lab uses electrophysiological approaches. Specifically, we use patch-clamp electrophyisiological techniques that involve placing a glass microelectrode onto a cell to record its electrical activity. In order to be useful in this technique, the glass electrode has to be pulled using heat to a very small tip which is the size of less than one micrometer. Thus, the glass pipette puller is the device that allow us to make glass electrodes useful for patch-clamp electrophysiology. Purpose and Objectives: The purpose of this acquisition is to procure a new Zeitz Glass Electrode puller to replace the one that was destroyed in a flood last year and was being used for very specialized experiments. Project requirements: Model: DMZ-Universal-Electrode-Puller Manufacturer: Zeitz Anticipated period of performance: Delivery is expected 30 days after receipt of order (ARO). Other important considerations: N/A Capability statement /information sought. Small business concerns that believe they possess the capabilities to provide the required products should submit documentation of their ability to meet each of the project requirements to the Contracting Officer. The capability statement must specifically address each of the project requirements separately. Additionally, the capability statement should include 1) the total number of employees, 2) the professional qualifications of personnel as it relates to the requirements outlined, 3) any contractor GSA Schedule contracts and/or other government-wide acquisition contracts (GWACs) by which all of the requirements may be met, if applicable, and 4) any other information considered relevant to this program. Small businesses must also provide their Company Name, DUNS number, Physical Address, and Point of Contact Information. Interested small businesses are required to identify their type of business, applicable North American Industry Classification System (NAICS) Code, and size standards in accordance with the Small Business Administration. The government requests that no proprietary or confidential business data be submitted in a response to this notice. However, responses that indicate the information therein is proprietary will be properly safeguarded for Government use only. Capability statements must include the name and telephone number of a point of contact having authority and knowledge to discuss responses with Government representatives. Capability statements in response to this market survey that do not provide sufficient information for evaluation will be considered non-responsive. When submitting this information, please reference the solicitation notice number. The respondent must also provide their DUNS number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HubZone, etc., pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2” x 11” paper size, with 1” top, bottom, left and right margins, and with single or double spacing. The information submitted must be in and outline format that addresses each of the elements of the project requirement and in the capability statement /information sought paragraphs stated herein. A cover page and an executive summary may be included but is not required. The response is limited to ten (10) page limit. The 10-page limit does not include the cover page, executive summary, or references, if requested. The response must include the respondents’ technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses. All responses to this notice must be submitted electronically to the Contract Specialist and Contracting Officer. Facsimile responses are NOT accepted. The response must be submitted to Cassandra Conley, at e-mail address Cassandra.conley@nih.gov. The response must be received on or before August 29, 2024, 10:00 am, Eastern Time. “Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).”","origin":"extract"},"notice_type":{"code":"r","label":"Sources Sought"},"schema_version":1,"solicitation_number":"75N95024Q00549","place_of_performance":{"city":{"name":"Bethesda"},"state":{"code":"MD"},"country":{"code":"USA"}}},{"dates":{"posted":"2024-09-04","response_deadline":{"raw":"2024-09-09T15:00:00-04:00","utc":"2024-09-09T19:00:00Z","date":"2024-09-09","time":"15:00:00","utc_offset_seconds":-14400}},"links":{"sam":"https://sam.gov/workspace/contract/opp/949e3b121b784d54980f443558331678/view"},"naics":{},"title":"Skin Biopsy Testing for Deep Phenotyping Projects at the National Institute of Neurological Diseases and Stroke (NINDS)","agency":{"office":{"name":"NATIONAL INSTITUTES OF HEALTH"},"subtier":{"code":"7529","name":"NATIONAL INSTITUTES OF HEALTH"},"department":{"code":"075","name":"HEALTH AND HUMAN SERVICES, DEPARTMENT OF"},"office_address":{"zip":"20892","city":"Bethesda","state":"MD","country":"US"},"organization_type":"AGENCY"},"status":{"active":false,"archive_date":"2024-09-24","archive_type":"auto15"},"contacts":[{"name":"Cassandra Conley","role":"primary","email":"cassandra.conley@nih.gov"}],"base_type":{"code":"s","label":"Special Notice"},"notice_id":"949e3b121b784d54980f443558331678","provenance":{"extract":{"url":"https://s3.amazonaws.com/falextracts/Contract%20Opportunities/Archived%20Data/FY2024_archived_opportunities.csv","etag":"\"d582488fe153a9f11bf629913d176ffc-137\"","fetched_at":"2026-09-16T19:07:39.720164Z","row_sha256":"cc3e9ad62a33411418e4932049da00884c756fb1be88486b8b3a2c2ec4079d4f","last_modified":"2026-09-13T14:47:40Z"},"updated_at":"2026-09-16T19:07:39.720164Z","first_seen_at":"2026-09-16T19:07:39.720164Z"},"description":{"text":"PRE-SOLICITATION NOTICE OF INTENT NON-COMPETITIVE SUBJECT Skin Biopsy Testing for Deep Phenotyping Projects at the National Institute of Neurological Diseases and Stroke (NINDS) REGULATORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures, and the procedures prescribed in FAR Subpart 13.106-1(b)(1), Soliciting from a single source. The resultant contract will include all applicable provisions and clauses of the FAR in effect through the Federal Acquisition Circular (FAC) 2023-04, dated June 2nd, 2023. DESCRIPTION Pursuant to FAR Subpart 5.2—Synopses of Proposed Contract Actions, THIS IS A PRE-SOLICITATION NOTICE OF INTENT TO AWARD A CONTRACT WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION. The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA), on behalf of the National Institute of Neurological Disorders and Stroke (NINDS) intends to negotiate and award a purchase order for a Skin Biopsy Testing for Deep Phenotyping Projects. The National Institutes of Health (NIH) is the nation’s leading medical research agency and the primary Federal agency whose mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting and making medical discoveries that improve people’s health and save lives. The National Institute of Neurological Disorders and Stroke (NINDS) is a part of the National Institutes of Health (NIH), which mission it is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease for all people. Small nerve fibers cannot be assessed by conventional means of measuring nerve function, such as nerve conduction velocity, amplitude, or quantitative sensory testing. Currently, the best scientific approach to studying small fiber neurons are collecting samples through skin punch biopsies and measurement of intraepidermal fiber density (IENFD). Autonomic function related to small nerve fibers can be studied through sweat gland fiber density (SGNFD). SGNFD requires particular expertise, as it requires time-consuming stereology and sample staining with Vasoactive Intestinal Peptide (VIP). Typical small fiber neuropathies typically follow a length-dependent pattern. However, alterations in small nerve fibers may not always follow such a pattern. For this reason, a two-site punch biopsy will be performed, with one sample collected from the distal lateral leg and one sample collected from the proximal lateral leg. NINDS has recently completed a deep phenotyping study of ME/CFS (Protocol 16-N-0058). As part of that protocol, a contract to perform small nerve fiber analysis was awarded to the Polydefkis lab at John Hopkins University (Contract HHSN271201800024C). The Polydefkis lab performed all of the specified work and met all terms of the contract. The results of this work have been compiled and are awaiting publication. Since the award of the aforementioned contract, NINDS has engaged in studying two other multisymptom illnesses, the Post-Acute Sequelae of COVID-19 (PASC) and Gulf War Illness (GWI). The same deep phenotyping framework is being applied to these conditions, with the intent to compare and contrast the results across conditions. For this reason, it is essential for these projects to have all measures performed using the same exact measures as performed as part of the ME/CFS protocol. There is a great deal of technical variability between labs that perform small nerve fiber analyses. Some of the lab-specific technical details are proprietary, making it impossible to ensure that results measured from different labs can be reliably compared to each other. Studies looking at interobserver variability show that just having different personnel assessing small neuron fiber samples can have a substantial impact on the results (Significant difference between three observers in the assessment of intraepidermal nerve fiber density in skin biopsy | BMC Neurology | Full Text (biomedcentral.com)). Comparisons between the measures made in the ME/CFS protocol and the upcoming PASC and GWI protocols will need to ensure analytic homogeneity to be successful. For this scientific reason, we are seeking a single-source justification to use the Polydefkis lab to analyze the samples being collected on PASC and GWI participants. ANTICIPATED SOURCE Company Name – Johns Hopkins Medicine Company Address – 1550 Orleans Street, Room 362 Baltimore, MD Contact Phone – (410) 955-3254 PERIOD OF PERFORMANCE The anticipated period of performance shall include one 12-month base period and two 12-month option periods as follows. Base: October 1, 2024 through September 30, 2025 Option 1: October 1, 2025 through September 30, 2026 Option 2: October 1, 2026 through September 30, 2027 PLACE OF PERFORMANCE N/A REASON FOR NON-COMPETITIVE ACTION The essential characteristics of the required services that limit the availability to a sole source are that the PVSS lab at NINDS has begun studying two other multi-symptom illnesses, the Post-acute sequelae of COVID-19 (PASC) and Gulf War Illness (GWI). The same deep phenotyping framework that has been used on past studies within the PVSS (contract HHSN271201800024C) is being applied to these new studies, with the intent to compare and contrast the results across conditions. For this reason, it is essential for these projects to have all measures performed the exact same way as the previous protocols. There is a great deal of technical variability between labs that perform small nerve fiber analyses. Some of the lab-specific technical details are proprietary, making it impossible to ensure that results measured from different labs can be reliably compared to each other. Using a different vendor for this purpose could compromise the integrity of the projects. CLOSING STATEMENT This synopsis is not a request for competitive proposals. All responsible sources may submit a capability statement, however, which shall be considered by the agency. Responses to this notice must include clear and convincing evidence of the offeror’s capability of fulfilling the requirement. In addition, the Unique Entity Identifier (UEI), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM). A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by 3:00 P.M., Eastern Standard Time on September 9, 2024. Responses must be submitted electronically to the Contract Specialist, Cassandra Conley, at cassandra.conley@nih.gov. Fax responses are not accepted.","origin":"extract"},"notice_type":{"code":"s","label":"Special Notice"},"schema_version":1,"solicitation_number":"75N95024Q00549","place_of_performance":{"city":{"name":"Bethesda"},"state":{"code":"MD"},"country":{"code":"USA"}}}],"due_at":"2024-08-29T14:00:00Z","due_date":"2024-08-29","closes_at":"2024-08-29T14:00:00Z","awardable":false,"dept_key":"d-075","dept_name":"HEALTH AND HUMAN SERVICES, DEPARTMENT OF","sub_key":"s-7529","sub_name":"NATIONAL INSTITUTES OF HEALTH","office_key":"o-n-NATIONALINSTITUTESOFHEALTH","office_name":"NATIONAL INSTITUTES OF HEALTH","state":"MD","county":"24031","county_name":"Montgomery County","city":"2407125","city_name":"Bethesda","country":"USA","winner_key":"EUJPXZASENV6","amount":null,"linked_awards":2,"cancelled":false,"archived":false,"updated_at":"2026-09-16T21:18:12.857524Z","principal_notice_id":"949e3b121b784d54980f443558331678","description":{"text":"PRE-SOLICITATION NOTICE OF INTENT NON-COMPETITIVE SUBJECT Skin Biopsy Testing for Deep Phenotyping Projects at the National Institute of Neurological Diseases and Stroke (NINDS) REGULATORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures, and the procedures prescribed in FAR Subpart 13.106-1(b)(1), Soliciting from a single source. The resultant contract will include all applicable provisions and clauses of the FAR in effect through the Federal Acquisition Circular (FAC) 2023-04, dated June 2nd, 2023. DESCRIPTION Pursuant to FAR Subpart 5.2—Synopses of Proposed Contract Actions, THIS IS A PRE-SOLICITATION NOTICE OF INTENT TO AWARD A CONTRACT WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION. The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA), on behalf of the National Institute of Neurological Disorders and Stroke (NINDS) intends to negotiate and award a purchase order for a Skin Biopsy Testing for Deep Phenotyping Projects. The National Institutes of Health (NIH) is the nation’s leading medical research agency and the primary Federal agency whose mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting and making medical discoveries that improve people’s health and save lives. The National Institute of Neurological Disorders and Stroke (NINDS) is a part of the National Institutes of Health (NIH), which mission it is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease for all people. Small nerve fibers cannot be assessed by conventional means of measuring nerve function, such as nerve conduction velocity, amplitude, or quantitative sensory testing. Currently, the best scientific approach to studying small fiber neurons are collecting samples through skin punch biopsies and measurement of intraepidermal fiber density (IENFD). Autonomic function related to small nerve fibers can be studied through sweat gland fiber density (SGNFD). SGNFD requires particular expertise, as it requires time-consuming stereology and sample staining with Vasoactive Intestinal Peptide (VIP). Typical small fiber neuropathies typically follow a length-dependent pattern. However, alterations in small nerve fibers may not always follow such a pattern. For this reason, a two-site punch biopsy will be performed, with one sample collected from the distal lateral leg and one sample collected from the proximal lateral leg. NINDS has recently completed a deep phenotyping study of ME/CFS (Protocol 16-N-0058). As part of that protocol, a contract to perform small nerve fiber analysis was awarded to the Polydefkis lab at John Hopkins University (Contract HHSN271201800024C). The Polydefkis lab performed all of the specified work and met all terms of the contract. The results of this work have been compiled and are awaiting publication. Since the award of the aforementioned contract, NINDS has engaged in studying two other multisymptom illnesses, the Post-Acute Sequelae of COVID-19 (PASC) and Gulf War Illness (GWI). The same deep phenotyping framework is being applied to these conditions, with the intent to compare and contrast the results across conditions. For this reason, it is essential for these projects to have all measures performed using the same exact measures as performed as part of the ME/CFS protocol. There is a great deal of technical variability between labs that perform small nerve fiber analyses. Some of the lab-specific technical details are proprietary, making it impossible to ensure that results measured from different labs can be reliably compared to each other. Studies looking at interobserver variability show that just having different personnel assessing small neuron fiber samples can have a substantial impact on the results (Significant difference between three observers in the assessment of intraepidermal nerve fiber density in skin biopsy | BMC Neurology | Full Text (biomedcentral.com)). Comparisons between the measures made in the ME/CFS protocol and the upcoming PASC and GWI protocols will need to ensure analytic homogeneity to be successful. For this scientific reason, we are seeking a single-source justification to use the Polydefkis lab to analyze the samples being collected on PASC and GWI participants. ANTICIPATED SOURCE Company Name – Johns Hopkins Medicine Company Address – 1550 Orleans Street, Room 362 Baltimore, MD Contact Phone – (410) 955-3254 PERIOD OF PERFORMANCE The anticipated period of performance shall include one 12-month base period and two 12-month option periods as follows. Base: October 1, 2024 through September 30, 2025 Option 1: October 1, 2025 through September 30, 2026 Option 2: October 1, 2026 through September 30, 2027 PLACE OF PERFORMANCE N/A REASON FOR NON-COMPETITIVE ACTION The essential characteristics of the required services that limit the availability to a sole source are that the PVSS lab at NINDS has begun studying two other multi-symptom illnesses, the Post-acute sequelae of COVID-19 (PASC) and Gulf War Illness (GWI). The same deep phenotyping framework that has been used on past studies within the PVSS (contract HHSN271201800024C) is being applied to these new studies, with the intent to compare and contrast the results across conditions. For this reason, it is essential for these projects to have all measures performed the exact same way as the previous protocols. There is a great deal of technical variability between labs that perform small nerve fiber analyses. Some of the lab-specific technical details are proprietary, making it impossible to ensure that results measured from different labs can be reliably compared to each other. Using a different vendor for this purpose could compromise the integrity of the projects. CLOSING STATEMENT This synopsis is not a request for competitive proposals. All responsible sources may submit a capability statement, however, which shall be considered by the agency. Responses to this notice must include clear and convincing evidence of the offeror’s capability of fulfilling the requirement. In addition, the Unique Entity Identifier (UEI), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM). A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by 3:00 P.M., Eastern Standard Time on September 9, 2024. Responses must be submitted electronically to the Contract Specialist, Cassandra Conley, at cassandra.conley@nih.gov. Fax responses are not accepted.","html":null,"origin":"extract"},"contacts":[{"name":"Cassandra Conley","role":"primary","email":"cassandra.conley@nih.gov"}],"place_of_performance":{"city":{"name":"Bethesda"},"state":{"code":"MD"},"country":{"code":"USA"}},"office_address":{"zip":"20892","city":"Bethesda","state":"MD","country":"US"},"naics_codes":[],"award":null,"attachments":[],"awards":[{"award_key":"CONT_AWD_75N95024P00628_7529_-NONE-_-NONE-","permalink":"https://www.usaspending.gov/award/CONT_AWD_75N95024P00628_7529_-NONE-_-NONE-/","piid":"75N95024P00628","parent_piid":null,"award_type":"PURCHASE ORDER","vendor_key":"EUJPXZASENV6","recipient_name":"AUTOMATE SCIENTIFIC, INC","recipient_uei":"EUJPXZASENV6","recipient_cage":"31NN3","recipient_city":"BERKELEY","recipient_state":"CA","sub_name":"National Institutes of Health","office_name":"NATIONAL INSTITUTES OF HEALTH NIDA","office_key":"o-75N950","first_action_date":"2024-09-18","last_action_date":"2024-09-18","actions":1,"obligated":"19065.24","current_total_value":"19065.24","potential_total_value":"19065.24","naics":"334516","psc":"6515","extent_competed":"NOT COMPETED UNDER SAP","set_aside":"NO SET ASIDE USED.","offers_received":1,"description":"AUTOMATE SCIENTIFIC ZEITZ GLASS PULLER REPLACEMENT PARTS","method":"solicitation","confidence":"high","evidence":["solicitation number 75N95024Q00549 equals the FPDS solicitation identifier","same sub-agency 7529"],"opportunity_key":null,"opportunity_title":null}],"related":[]}